Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7621 AL 7635

Manual Lymph Drainage for Alzheimer's Dementia: A Clinical Trial Whose Time Has Come?

Erickson RP, Bernas MJ, Witte MH.

Lymphology. 2025;58(2):43-45.

Special Issue: "New Trends in Alzheimer's Disease Research: From Molecular Mechanisms to Therapeutics: 2nd Edition"

Cacabelos R.

Int J Mol Sci. 2025 Jul 25;26(15):7175. doi: 10.3390/ijms26157175.

Introduction to the DETeCD-ADRD special issue

Dickerson BC, Atri A.

Alzheimers Dement. 2025 Feb;21(2):e14483. doi: 10.1002/alz.14483. Epub 2024 Dec 28.

Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia

Loi SM, Kang MJ.

Australas Psychiatry. 2025 Aug;33(4):599-602. doi: 10.1177/10398562251355157. Epub 2025 Jun 23.

Does weak gamma entrainment still work? Rethinking the comfort-efficacy trade-off in 40 Hz sensory stimulation

Tseng P.

J Alzheimers Dis. 2025 Dec;108(4):1517-1519. doi: 10.1177/13872877251389153. Epub 2025 Oct 24.

Recent advances in the detection and management of motor dysfunction in Alzheimer's disease

Marogianni C, Siokas V, Dardiotis E.

Psychiatriki. 2025 Jul 2;36(2):97-100. doi: 10.22365/jpsych.2025.012. Epub 2025 May 14.

History repeats itself: A new trivializing term for a potentially life-threatening side effect of antibody Alzheimer's disease therapy

Høilund-Carlsen PF, Barrio JR.

J Alzheimers Dis. 2025 Aug;106(3):925-927. doi: 10.1177/13872877251350295. Epub 2025 Jun 19.

Imaging the Treatment of Alzheimer Disease: 2030 Could Look Very Different

Shepherd TM.

Radiology. 2025 Jun;315(3):e251704. doi: 10.1148/radiol.251704.

Gamma sensory stimulation: Investigating human brain response to optimize clinical translation

Manippa V.

J Alzheimers Dis. 2026 Feb;109(4):1628-1629. doi: 10.1177/13872877251407709. Epub 2025 Dec 19.

Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease

Rosen J, Jessen F.

J Prev Alzheimers Dis. 2025 Apr;12(4):100102. doi: 10.1016/j.tjpad.2025.100102. Epub 2025 Feb 25.

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review

Wang Y, Yu Q, Chen B, Zhou J, Li Z, Liao W, Liu J, Yang A.

BMC Neurol. 2025 Jul 7;25(1):281. doi: 10.1186/s12883-025-04302-5.

Tolerability of rivastigmine transdermal patch in patients with Alzheimer's disease: a narrative review

García Ribas G, Ferrer-Picón E.

Expert Opin Drug Saf. 2026 Apr;25(4):643-655. doi: 10.1080/14740338.2025.2576520. Epub 2025 Oct 31.

Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study

Desai RJ, Varma VR, Mahesri M, Lee SB, Freedman A, Gerhard T, Segal J, Vine S, Ritchey MBE, Horton DB, Thambisetty M.

Clin Pharmacol Ther. 2025 Apr;117(4):1039-1050. doi: 10.1002/cpt.3583. Epub 2025 Feb 11.

Dual single nucleotide polymorphisms typing of apolipoprotein E gene based on double restriction endonuclease with lambda exonuclease and triple helix molecular switch assistance

Lin G, Liang W, He Q, Wang Y, Yang X.

Biosens Bioelectron. 2025 Jun 15;278:117365. doi: 10.1016/j.bios.2025.117365. Epub 2025 Mar 11.

Health App Review Tool (HART): Content validation through expert panel review

Moon S, Best K, Choi YK, Faieta J.

Assist Technol. 2025 Feb 14;37(sup1):S3-S8. doi: 10.1080/10400435.2024.2337857. Epub 2024 Apr 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias